Solcitinib – 25 mg

Brand:
Cayman
CAS:
1206163-45-2
Storage:
-20
UN-No:
Non-Hazardous - /

Solcitinib is an inhibitor of JAK1 (IC50s = 100 nM for JAK1 and JAK2, respectively).{40322} Formulations containing solcitinib have been evaluated in clinical trials for the treatment of moderate-to-severe psoriasis, ulcerative colitis, and systemic lupus erythematosus (SLE).{40320} However, clinical trials using formulations containing solcitinib for the treatment of SLE were terminated early due to elevated liver enzymes and at least one case of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome.{40321}  

 

Available on backorder

SKU: 23439 - 25 mg Category:

Description

A JAK1 inhibitor (IC50s = 100 nM for JAK1 and JAK2, respectively)


Formal name: N-[5-[4-[(3,3-dimethyl-1-azetidinyl)carbonyl]phenyl][1,2,4]triazolo[1,5-a]pyridin-2-yl]-cyclopropanecarboxamide

Synonyms:  GLPG0778|GSK2586184

Molecular weight: 389.5

CAS: 1206163-45-2

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors|JAK Family||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cell Biology|Cell Signaling|JAK Signaling||Research Area|Immunology & Inflammation|Autoimmunity|Lupus||Research Area|Immunology & Inflammation|Gastric Disease|Ulcerative Colitis